ACADIA PHARMACEUTICALS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ACADIA PHARMACEUTICALS INC. (ACAD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $52.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $52.56M, a 22.10% decline from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $67.47M, a 1.46% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $66.50M, a 2.32% decline from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $68.08M, a 6.67% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|
| 2025-12-31 | $52.56M 10-K · filed 2026-02-26 |
| 2024-12-31 | $67.47M 10-K · filed 2026-02-26 |
| 2023-12-31 | $66.50M 10-K · filed 2026-02-26 |
| 2022-12-31 | $68.08M 10-K · filed 2025-02-27 |
| 2021-12-31 | $63.82M 10-K · filed 2024-02-28 |
| 2020-12-31 | $84.44M 10-K · filed 2023-02-28 |
| 2019-12-31 | $82.80M 10-K · filed 2022-03-01 |
| 2018-12-31 | $82.31M 10-K · filed 2021-02-25 |
| 2017-12-31 | $75.88M 10-K · filed 2020-02-27 |
| 2016-12-31 | $56.13M 10-K · filed 2019-02-27 |
| 2015-12-31 | $40.19M 10-K · filed 2018-02-27 |
| 2014-12-31 | $16.04M 10-K · filed 2017-02-28 |
| 2013-12-31 | $5.71M 10-K · filed 2016-02-29 |
| 2012-12-31 | $1.93M 10-K · filed 2015-02-26 |
| 2011-12-31 | $1.60M 10-K · filed 2014-02-27 |
| 2010-12-31 | $1.58M 10-K · filed 2013-03-12 |
| 2009-12-31 | $2.13M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |